Daily Stock Analysis, ATRA, Atara Biotherapeutics Inc, priceseries

Atara Biotherapeutics Inc. Daily Stock Analysis
Stock Information
Open
39.06
Close
39.43
High
39.57
Low
38.51
Previous Close
39.23
Daily Price Gain
0.20
YTD High
39.98
YTD High Date
Feb 12, 2019
YTD Low
27.85
YTD Low Date
Jan 3, 2019
YTD Price Change
4.17
YTD Gain
11.83%
52 Week High
54.45
52 Week High Date
May 21, 2018
52 Week Low
27.85
52 Week Low Date
Jan 3, 2019
52 Week Price Change
-7.62
52 Week Gain
-16.20%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 3. 2017
14.20
Feb 21. 2017
14.96
11 Trading Days
5.32%
Link
LONG
Mar 8. 2017
17.30
Mar 15. 2017
19.03
5 Trading Days
10.02%
Link
LONG
Jan 5. 2018
18.50
Feb 2. 2018
33.88
19 Trading Days
83.14%
Link
LONG
May 11. 2018
42.75
May 29. 2018
48.81
11 Trading Days
14.18%
Link
Company Information
Stock Symbol
ATRA
Exchange
NasdaqGS
Company URL
http://www.atarabio.com
Company Phone
650-278-8930
CEO
Issac E. Ciechanover
Headquarters
California
Business Address
611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001604464
About

Atara Biotherapeutics, Inc. operates as a clinical stage biopharmaceutical company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Description

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.